Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2013 | 10:15am CEST

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:
www.drreddys.com

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at [email protected]/ +91-40-66834297
Saunak Savla at [email protected]/ +91-40-49002135
Milan Kalawadia (USA) at [email protected]/ +1 908-203-4931

Media:
S Rajan at [email protected]/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DR.REDDY'S LABORATORIES LT
10/16 DR.REDDY'S LABORATORIES LTD : UPCOMING DEADLINE: Lundin Law PC Announces Securit..
10/16 DR.REDDY'S LABORATORIES LTD : RDY The Law Offices of Vincent Wong Reminds Invest..
10/16 DR REDDY LABORATORIES : . Reddy's to Release Q2 FY18 Results on October 31, 2017
10/14 DR.REDDY'S LABORATORIES LTD : UPCOMING DEADLINE: Khang & Khang LLP Announces Sec..
10/13 INDIAN ADRS END MIXED : HDFC Bank, Vedanta gain while Dr reddy fell
10/13 NICOTINE GUM : Enorama signs pact with drl
10/12 DR.REDDY'S LABORATORIES LTD : DEADLINE APPROACHING: Lundin Law PC Announces Secu..
10/11 DR.REDDY'S LABORATORIES LTD : APPROACHING DEADLINE: Khang & Khang LLP Announces ..
10/11 DR.REDDY'S LABORATORIES LTD : Levi & Korsinsky, LLP Reminds Shareholders of Dr. ..
10/10 DR.REDDY'S LABORATORIES LTD : DEADLINE ALERT: Lundin Law PC Announces Securities..
More news
News from SeekingAlpha
09/21 PREMARKET GAINERS AS OF 9 : 05 am
09/21 Premarket analyst action - healthcare
09/19 MYLAN : Time To Sell?
09/12 Indivior Could Fall Further Once Generic Suboxone Arrives
09/06 Dr. Reddy's Laboratories launches Metaxalone Tablets, USP in the U.S.
Financials ( INR)
Sales 2018 151 B
EBIT 2018 17 339 M
Net income 2018 13 703 M
Debt 2018 33 036 M
Yield 2018 0,81%
P/E ratio 2018 28,22
P/E ratio 2019 18,29
EV / Sales 2018 2,81x
EV / Sales 2019 2,41x
Capitalization 391 B
Chart DR.REDDY'S LABORATORIES LT
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Technical analysis trends DR.REDDY'S LABORATORIES LT
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 39
Average target price 2 579  INR
Spread / Average Target 9,5%
EPS Revisions
Managers
NameTitle
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
DR.REDDY'S LABORATORIES LTD-22.95%6 037
JOHNSON & JOHNSON18.42%366 178
NOVARTIS13.23%225 160
ROCHE HOLDING LTD.5.20%216 764
PFIZER11.88%216 409
MERCK AND COMPANY7.68%172 887